title: Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
authors: Department of Internal Medicine, Gentofte Hospital, Hellerup, Denmark. t.vilsboll@dadlnet.dk
authors: Tina
authors: T
authors: Vilsbøll
authors: Milan
authors: M
authors: Zdravkovic
authors: Tu
authors: T
authors: Le-Thi
authors: Thure
authors: T
authors: Krarup
authors: Ole
authors: O
authors: Schmitz
authors: Jean-Pierre
authors: JP
authors: Courrèges
authors: Robert
authors: R
authors: Verhoeven
authors: Ingrid
authors: I
authors: Bugánová
authors: Sten
authors: S
authors: Madsbad
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide; D010919:Placebos; D012449:Safety; D015431:Weight Loss
chemical_list: D001786:Blood Glucose; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D010919:Placebos